Purchase Order 75N98026P01140

<p>The National Cancer Institute issued a delivery order to Global Life Sciences Solutions USA LLC on May 13, 2026, for supply of an Amersham Typhoon IP biomolecular imager, with a ceiling value of $64,769.64.</p> <p>Place of performance is Marlborough, MA. Ultimate completion date is December 31, 2026. This is a firm fixed-price delivery order issued under the Multiple Award Schedule (MAS), with no small business set-aside.</p>

The National Cancer Institute issued a purchase order to Li-Cor, Inc. on June 12, 2026, for one LI-COR Biotech Odyssey M Chemi/Fluor Imaging Bundle Standard system valued at $92,376.00, with completion expected by July 12, 2026. The order is firm fixed price and carries no set-aside designation. Place of performance is Lincoln, Nebraska (the vendor's manufacturing location); delivery and installation occur at the National Cancer Institute's Laboratory of Human Carcinogenesis in Bethesda,...

<p>The National Cancer Institute awarded a $38,300 purchase order to Mediso USA LLC on September 17, 2018, for high-energy collimators for NanoSpect/CT imaging equipment. Work is performed in Boston, Massachusetts, under firm fixed-price terms, with an ultimate completion date of September 16, 2019. The order originated from a pre-solicitation opportunity posted September 12, 2018, with award decision made within five days of the stated due date.</p>

<p>The National Cancer Institute awarded a purchase order to Biospace Lab USA, Inc. for $21,004.00 on February 26, 2020, with an ultimate completion date of March 7, 2021. The order is for photon imager services, performed at Columbia, Maryland. Pricing is firm fixed price with no small business set-aside.</p>

The National Cancer Institute issued a purchase order to Li-Cor Biotech, LLC on June 12, 2026, for one Odyssey M Chemi/Fluor Imaging Bundle Standard imaging system, valued at $92,376.00 and due for completion by July 12, 2026. The acquisition was sole-source, non-competitive under FAR Parts 12 and 13, justified on a brand-name basis. Place of performance is Lincoln, Nebraska. The system includes four solid-state laser diodes (488, 520, 685, and 785 nm wavelengths), sCMOS fluorescence...

The National Cancer Institute awarded a purchase order to Intelligent Imaging Innovations, Inc. for an intelligent imaging innovation lattice light sheet system with four-color and two-camera capability and analysis workstation on August 19, 2019, with a ceiling value of $775,281.70. The order carries a total small business set-aside. Place of performance is Rockville, Maryland. The contract is firm fixed price and ultimate completion is December 19, 2019. The solicitation was posted July 3,...

<p>The National Cancer Institute awarded a purchase order to Mim Software Inc. valued at $7,350.00 on January 1, 2014, to continue scans using the Gemini PET/CT scanner and view patient images. Place of performance is Bethesda, Maryland. The order carries firm fixed pricing with an ultimate completion date of December 31, 2014.</p>

<p>The National Cancer Institute awarded a purchase order to Biovision Technologies, Inc., a small business, for $23,860.40 on September 7, 2017, with an ultimate completion date of October 8, 2017. Place of performance is Bethesda, Maryland. The order calls for precision scientific imaging equipment or related optical/microscopy instrumentation. Pricing is firm fixed price.</p>

<p>The National Cancer Institute awarded a purchase order to Yokogawa Corporation of America for $643,305.42 on May 27, 2026 to procure a Yokogawa CV8000 high-throughput spinning disk confocal microscope. Performance will occur in Japan with an ultimate completion date of September 26, 2026. The solicitation was posted May 1, 2026 with a due date of May 20, 2026. The order uses firm fixed-price pricing with no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Lablogic Systems, Inc. valued at $16,300 on July 15, 2019. Performance is in Tampa, Florida, with ultimate completion by August 15, 2019. The order is firm fixed price on a full-and-open basis. Specific scope details are not provided in the award notice.</p>